HIV integrase inhibitors with nucleobase scaffolds: Discovery of a highly potent anti-HIV agent

Journal of Medicinal Chemistry

Volumn 49, Issue 2, 2006, Pages 445-447

  Nair, Vasu ^a   Chi, Guochen ^a   Ptak, Roger ^b   Neamati, Nouri ^c  

^a UNIVERSITY OF GEORGIA   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 (1,3 DIBENZYL 1,2,3,4 TETRAHYDRO 2,4 DIOXOPYRIMIDIN 5 YL) 2 HYDROXY 4 OXO BUT 2 ENOIC ACID; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETA KETO ACID; INTEGRASE INHIBITOR; NUCLEIC ACID BASE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; TRANSACTIVATION; VIROGENESIS; VIRUS REPLICATION;

BINDING SITES; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; HYDROXYBUTYRATES; KETO ACIDS; LEUKOCYTES, MONONUCLEAR; MODELS, MOLECULAR; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; URACIL;

EID: 31544474642     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0508890     Document Type: Article

References (29)

1. Fauci, A. S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988, 239, 617-622.
2. Katz, R. A.; Skalka, A. M. The retroviral enzymes. Annu. Rev. Biochem. 1994, 63, 133-173.
3. Frankel, A. D.; Young, J. A. T. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 1998, 67, 1-25.
4. De Clercq, E. Strategies in the design of antiviral drugs. Nature Rev. Drug Discovery 2002, 1, 13-25.
5. De Clercq, E. In search of a selective antiviral chemotherapy. Clin. Microbiol. Rev. 1997, 10, 674-693.
6. Johnson, S. C.; Gerber, J. G. Advances in HIV/AIDS therapy. In Advances in Internal Medicine; Schrier, R. W.; Baxter, J. D.; Dzau, V. J.; Fauci, A. S., Eds.; Mosby: St. Louis, 2000; Vol. 45, pp 1-40.
7. Nair, V.; St. Clair, M. H.; Reardon, J. E.; Krasny, H. C.; Hazen, R. J.; Paff, M. T.; Boone, L. R.; Tisdale, M.; Najera, I.; Dornsife, R. E.; Averett, D. R.; Borroto-Esoda, K.; Yale, J. L.; Zimmerman, T. P.; Rideout, J. L. Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)-tetra-hydro-2(S)-furanmethanol. Antimicrob Agents Chemother. 1995, 39, 1993-1999.
8. De Clercq, E. New approaches toward anti-HIV chemotherapy. J. Med. Chem. 2005, 48, 1297-1313.
9. Pommier, Y.; Johnson A. A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nature Rev. Drug Discovery 2005, 4, 236-248.
10. Nair, V. Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agents. Frontiers Med. Chem. 2005, 2, 3-20.
11. Dayam, R.; Neamati, N. Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Curr. Pharm. Design 2003, 9, 1789-1802.
12. Asante-Appiah, E.; Skalka, A. M. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 1999, 52, 351-369.
13. Esposito, D.; Craigie, R. HIV integrase structure and function. Adv. Virus Res. 1999, 52, 319-333.
14. Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Engelman, A.; Craigie, R.; Davies, D. R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994, 266, 1981-1986.
15. Wu, Y.; Marsh, J. W. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 2001, 293, 1503-1506.
16. Espeseth, A. S.; Felock, P.; Wolfe, A. Witmer, M.; Grobler, J.; Anthony, N.; Egbertson, M.; Melamed, J. Y.; Young, S.; Hamlll, T.; Cole, J. L.; Hazuda D. J. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 11244-11249.
17. Mazumder, A.; Uchida, H.; Neamati, N.; Sunder, S.; Jaworska-Maslanka, M.; Wickstrom, E.; Zeng, F.; Jones, R. A.; Mandes, R. F.; Chenault, H. K.; Pommier, Y. Probing interactions between viral DNA and human immunodeficiency virus type 1 integrase using dinucleotides. Mol. Pharmacol. 1997, 51, 567-575.
18. Taktakishvili, M.; Neamati, N.; Pommier, Y.; Pal, S.; Nair, V. Recognition and inhibition of HIV integrase by novel dinucleotides. J. Am. Chem. Soc. 2000, 122, 5671-5677.
19. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
20. Wai, J. S.; Egbertson, M. S.; Payne, L. S.; Fisher, T. E.; Embrey, M. W.; Tran, L. O.; Melamed, J. Y.; Langford, H. M.; Guare, J. P., Jr.; Zhuang, L.; Grey, V. E.; Vacca, J. P.; Holloway, M. K.; Naylor-Olsen, A. M.; Hazuda, D. J.; Felock, P. J.; Wolfe, A. L.; Stillmock, K. A.; Schleif, W. A.; Gabryelski, L. J.; Young, S. D. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem. 2000, 43, 4923-4926.
21. Marchand, C.; Zhang, X.; Pais, G. C. G.; Cowansage, K.; Neamati, N.; Burke, T. R., Jr.; Pommier, Y. Structural determinants for HIV-1 integrase inhibition by β-diketo acids. J. Biol. Chem. 2002, 277, 12596-12603.
22. Hazuda, D. J.; Young, S. D.; Guare, J. P.; Anthony, N. J.; Gomez, R. P.; Wai, J. S.; Vacca, J. P.; Handt, L.; Motzel, S. L.; Klein, H. J.; Dornadula, G.; Danovich, R. M.; Witmer, M. V.; Wilson, K. A. A.; Tussey, L.; Schleif, W. A.; Gabryelski, L. S.; Jin, L.; Miller, M. D.; Casimiro, D. R.; Emini, E. A.; Shiver, J. W. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004, 305, 528-532.
23. Grobler, J. A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A. S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J. S.; Young, S.; Vacca, J.; Hazuda, D. J. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 6661-6666.
24. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13040-13043.
25. Yoshinaga, T.; Sato, A.; Fujishita, T.; Fujiwara, T. S-1360: in vitro activity of a new HIV-1 integrase inhibitor in clinical development. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA; Feb 24-28, 2002; Abstract 8, p 55.
26. Data given in Tables 1 for compound S-1360 are those cited by Billich, A. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Invest. Drugs 2003, 4, 206-209.
27. Pannecouque, C.; Pluymers, W.; Van Maele, B.; Tetz, V.; Cherepanov, P.; De Clercq, E.; Witvrouw, M.; Debyser, Z. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr. Biol. 2002, 12, 1169-1177.
28. Pais, G. C. G.; Zhang, X.; Marchand, C.; Neamati, N.; Cowansage, K.; Svarovskaia, E. S.; Pathak, V. K.; Tang, Y.; Nicklaus, M.; Pommier, Y.; Burke, T. R., Jr. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J. Med. Chem. 2002, 45, 3184-3194.
29. Mazumder, A.; Neamati, N.; Sundar, S.; Owen, J.; Pommier, Y. Retroviral integrase: a novel target in antiviral drug development and basic in vitro assays with purified enzyme. In Antiviral Methods and Protocols; Kinchington, D.; Schinazi, R. Eds.; Humana: Totowa, 1999; Vol. 24, pp 327-338.